Abstract:The immune system can suppress tumour development both by eliminating malignant cells and by preventing the outgrowth and spread of cancer cells that resist eradication1. Clinical and experimental data suggest that the latter mode of control—termed cancer–immune equilibrium1—can be maintained for prolonged periods of time, possibly up to several decades2–4. Although cancers most frequently originate in epithelial layers, the nature and spatiotemporal dynamics of immune responses that maintain cancer–immune equilibrium in these tissue compartments remain unclear. Here, using a mouse model of transplantable cutaneous melanoma5, we show that tissue-resident memory CD8+ T cells (TRM cells) promote a durable melanoma–immune equilibrium that is confined to the epidermal layer of the skin. A proportion of mice (~40%) transplanted with melanoma cells remained free of macroscopic skin lesions long after epicutaneous inoculation, and generation of tumour-specific epidermal CD69+ CD103+ TRM cells correlated with this spontaneous disease control. By contrast, mice deficient in TRM formation were more susceptible to tumour development. Despite being tumour-free at the macroscopic level, mice frequently harboured melanoma cells in the epidermal layer of the skin long after inoculation, and intravital imaging revealed that these cells were dynamically surveyed by TRM cells. Consistent with their role in melanoma surveillance, tumour-specific TRM cells that were generated before melanoma inoculation conferred profound protection from tumour development independently of recirculating T cells. Finally, depletion of TRM cells triggered tumour outgrowth in a proportion (~20%) of mice with occult melanomas, demonstrating that TRM cells can actively suppress cancer progression. Our results show that TRM cells have a fundamental role in the surveillance of subclinical melanomas in the skin by maintaining cancer–immune equilibrium. As such, they provide strong impetus for exploring these cells as targets of future anticancer immunotherapies.

Transient Regulatory-T-cell Interruption Promotes Skin-Resident Memory T Cells Mediated Tumor Protection

Cancer Immunotherapies Targeting Tumor-Associated Regulatory T Cells

Precise Spatiotemporal Interruption of Regulatory T-cell-Mediated CD8(+) T-cell Suppression Leads to Tumor Immunity

Resident memory (TRM) cells sustain immunity to cancer at sites of frequent metastasis

How to Detour Treg Cells in T Cell-Based Antitumor Immune Therapy

Immunotherapy of Cancer by Targeting Regulatory T cells

Infiltrating treg reprogramming in the tumor immune microenvironment and its optimization for immunotherapy

TGF-β-dependent Lymphoid Tissue Residency of Stem-Like T Cells Limits Response to Tumor Vaccine

Peripheral-derived regulatory T cells contribute to tumor-mediated immune suppression in a nonredundant manner

Tissue-resident memory CD8+ T cells promote melanoma–immune equilibrium in skin

T Regulatory Cells Induced Tumor Immune Tolerance

Reprogramming of regulatory T cells in inflammatory tumor microenvironment: can it become immunotherapy turning point?

Acquisition of suppressive function by conventional T cells limits antitumor immunity upon Treg depletion

Conserved transcriptional connectivity of regulatory T cells in the tumor microenvironment informs new combination cancer therapy strategies

Regulatory T cells in tumor immunity

Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?

The Potential of Tissue-Resident Memory T Cells for Adoptive Immunotherapy against Cancer

Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects

Immunoregulatory T cells in tumor immunity

Abstract 2919: Targeting regulatory T cells to boost immunity against melanoma

Regulatory T Cells Nanoextinguisher to Manipulate Multiple Immune Evasion for Immunotherapy